Pfizer Inc (PFE): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Pfizer ( PFE) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 1.8%. By the end of trading, Pfizer fell $0.69 (-2.2%) to $30.65 on average volume. Throughout the day, 34,565,936 shares of Pfizer exchanged hands as compared to its average daily volume of 25,422,000 shares. The stock ranged in price between $30.52-$31.34 after having opened the day at $31.31 as compared to the previous trading day's close of $31.34. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 44.1%, AVANIR Pharmaceuticals ( AVNR), down 29.8%, Curis ( CRIS), down 11.2% and Oramed Pharmaceuticals ( ORMP), down 11.0%.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $204.7 billion and is part of the health care sector. The company has a P/E ratio of 20.9, above the S&P 500 P/E ratio of 17.7. Shares are up 25.9% year to date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, CytRx Corporation ( CYTR), up 68.2%, Rexahn Pharmaceuticals ( RNN), up 21.5%, Echo Therapeutics ( ECTE), up 14.7% and NanoString Technologies ( NSTG), up 11.0%.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

The 6 Medications Being Used to Tackle the Opioid Epidemic

Dow, S&P 500 Set New Records as Fed Moves to Unwind Balance Sheet

Stocks In Negative Territory as Chances for December Hike Surge

The Wait for 'Milestone' Fed Meeting Keeps Stocks in Flux